Sixteen percent of COVID-19 cases may only present with gastrointestinal symptoms, which include nausea, vomiting, diarrhea
FRIDAY, Nov. 6, 2020 (HealthDay News) — Gastrointestinal manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection occur in about 18 percent of patients and can include loss of appetite, nausea, vomiting, and diarrhea, according to a review recently published in Abdominal Radiology.
Kevin Lui, from the University of Alberta in Edmonton, Canada, and colleagues conducted a systematic review that included case reports and series discussing radiologic manifestations of SARS-CoV-2 infection in abdominal imaging studies. Data from 36 studies were included in a qualitative synthesis.
The researchers found that the prevalence of gastrointestinal symptoms was about 18 percent; symptoms included loss of appetite, nausea, vomiting, diarrhea, and abdominal pain. Of COVID-19 cases, 16 percent may only present with gastrointestinal symptoms. Many patients who only present with gastrointestinal symptoms show incidental evidence of COVID-19 through abdominal computed tomography imaging at the lung bases. Abdominal imaging findings reported to date include small and large bowel wall thickening, fluid-filled colon, pneumatosis intestinalis, pneumoperitoneum, intussusception, and ascites.
“Gastrointestinal manifestations of COVID-19 have been increasingly recognized,” the authors write. “Identifying these features on abdominal imaging highlight the need to consider and evaluate for other manifestations of COVID-19 such as lung parenchymal findings.”
Relapse Rare After Appendiceal Adenocarcinoma Resection
Metabolic Dysfunction-Associated Steatotic Liver Disease Linked to Higher Odds of Eosinophilic Esophagitis
Eosinophilic Esophagitis Prevalence May Be Higher Than Thought in Pediatric Patients With Asthma
Antibiotic Prescribing >95 Percent for Uncomplicated Diverticulitis
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus
Therapies Compared for Newly Diagnosed Multiple Sclerosis
Initial Rx Length Tied to Long-Term Use of Z-Drugs
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML